The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform

Recursion和Exscientia两家人工智能驱动的药物发现和开发公司的业务合并已经完成，Exscientia成为Recursion的全资子公司，创建了一个垂直集成和技术支持的药物发现平台

Exscientia ADSs ceased trading and will be delisted from Nasdaq. “I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With more than 10 clinical and preclinical programs in the internal pipeline, more than 10 partnered programs and over $450M in upfront and realized milestone payments received from partners to date out of more than $20B possible, we are advancing a flywheel of discovery and creating value in our pipeline through technology.”.

Exscientia ADSs停止交易，将从纳斯达克退市。“我相信Exscientia和Recursion令人难以置信的团队和平台的结合使我们成为人工智能药物发现和开发领域的领导者，”Recursion联合创始人兼首席执行官克里斯·吉布森博士说。“随着10多个临床和临床前项目在内部管道中，10多个合作项目和超过4.5亿美元的预付款，以及迄今为止从合作伙伴那里收到的超过200亿美元的里程碑付款，我们正在通过技术推进发现和创造价值的飞轮。”。

Type: industry

类型：工业